Compare CIGI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIGI | RVMD |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | Canada | United States |
| Employees | N/A | 883 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 19.1B |
| IPO Year | 1995 | N/A |
| Metric | CIGI | RVMD |
|---|---|---|
| Price | $102.44 | $94.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 18 |
| Target Price | ★ $174.00 | $117.33 |
| AVG Volume (30 Days) | 315.2K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.74 | N/A |
| Revenue Next Year | $8.04 | $408.69 |
| P/E Ratio | $57.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.97 | $29.17 |
| 52 Week High | $171.20 | $124.49 |
| Indicator | CIGI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 39.23 |
| Support Level | $98.97 | $74.64 |
| Resistance Level | $149.12 | $107.45 |
| Average True Range (ATR) | 3.81 | 3.20 |
| MACD | -0.16 | -0.47 |
| Stochastic Oscillator | 17.11 | 10.06 |
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.